Patient Support

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.

Why manufacturers should leverage technology to address low adherence rates.

Syneos Health's Kim Plesnarski uncovers the key issues that customers are currently trying to address, including the retail shift from small-molecule products to biologics.

Patients should not have to wait to access the medication they need.

The new option will help patients receive life-saving medications at an even quicker rate.

A study of patients with the long-term conditions who are required to switch to high-deductible health plans could potentially be more likely to experience diabetes complications than those who stay in standard insurance plans.

In an interview with Pharma Commerce Associate Editor Don Tracy, Adrianna Nava, PhD, MPA, MSN, RN, President, National Association of Hispanic Nurses (NAHN) talks about the organization's mission and goals.

A multiple myeloma survivor shares his story, including how patient assistance made a positive impact.

Presentation discusses the evolution of the patient assistance landscape, while presenting ways to collaborate.

Presentation offers insight on this aforementioned model that assists retail and specialty-lite brands.

Fireside chat uncovers ways to leverage this technology in order to boost medication adherence, engagement, and outcomes.

Panel discusses PAN Foundation’s inaugural “State of Patient Access” report, and dives deep into patient challenges.

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.

A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

An investigation evaluates whether SNAP benefits can also influence hypertension patients’ lack of medication adherence.

The CRO’s FortreaRx doubles in size, including a boost in cold chain storage, while also continuing to improve its patient access services.

Cabenuva (cabotegravir + rilpivirine) showed superior efficacy in maintaining viral load suppression in patients with HIV compared with standard of care daily oral antiretroviral treatment.

Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.

Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.

And the need to boost awareness of this critical healthcare resource.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.